Chuikyo on FY2024 Reimbursement Reform

• Chuikyo Reps Criticize Manufacturers’ Price Cuts after Unprofitability Re-Pricing
  August 3, 2023

• Chuikyo Medical Device Pricing Body Calls for Clearer Reimbursement Criteria for SaMDs
  July 27, 2023

• Chuikyo Wary of Abolishing Spillover Rule, Positive on Reviewing Market Expansion Re-Pricing
  July 27, 2023

• Chuikyo Divided Over Raising Premium Rates for Listed Products, Extending Evaluation Data
  July 27, 2023

• Chuikyo OKs CEA Organization’s Reform Directions for FY2024
  July 13, 2023

• Chuikyo Reps Want More Data from Industry to Review Launch Premiums
  July 13, 2023

• Chuikyo Discusses Price Maintenance Premium, Focus Is on Company Criteria
  July 13, 2023

• Chuikyo Split over Drug Lags and Losses, Rapid Introduction Evaluation System
  July 13, 2023

• Amid High Turnover Rate, JPWA Presses for New System to Support Drug Prices
  July 7, 2023

• Industry Stresses Stronger Price Support Rule to Ensure Stable Supplies
  July 7, 2023

• Reflect Societal Values in Pricing of Regenerative Medicines: FIRM
  July 7, 2023

• JPMA Pushes Simple Price Maintenance for Innovative Meds; PhRMA, EFPIA in Sync
  July 6, 2023

• Pharma Groups Float New Methods to Evaluate Innovative Drugs for 2024 Reform
  July 6, 2023

• Discuss Drug Price Revision System That Doesn’t Cause Yakkasa: FPMAJ Chair
  July 6, 2023

• Japan, US, Europe Trade Groups Urge Japan to Abolish “Spillover” Re-Pricing
  July 6, 2023

• 5 FPMAJ-Affiliated Bodies Petition Expanded Coverage, Eased Criteria for Essential Drug Rule
  July 6, 2023

• Chuikyo Kicks Off Debates toward FY2024 Drug Price Reform
  June 22, 2023

• Chuikyo OKs CEA Discussion Timeline for FY2024 Reform; Industry Hearing Set for August, November
  April 27, 2023

ページ